This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
== Salary == The salary for a diener varies based upon education, experience, employer, and employment location (i.e., city or state of employment). The salary is typically between $25,000 and $38,000 annually.
=== Early life and education === Gish, a twin, was born in White City, Kansas, the youngest of nine children. He served in World War II, attaining the rank of captain, and was awarded the Bronze Star. Gish graduated from the University of California, Los Angeles, with a Bachelor of Science in 1949. He then earned a Ph.D. in biochemistry from the University of California, Berkeley, in 1953. His doctoral dissertation was titled, "I. The application of p-nitrobenzyl chloroformate to peptide synthesis. II. Para-nitrobenzyloxycarbonyl derivatives of amino acids. III. A method of synthesis of arginyl peptides".
== Research == A study on 7-OH-MIT's safety was unable to identify a lethal dose orally due to a lack of deaths occurring. In a later part of the same study they found both mitragynine and 7-OH-MIT to be able to cause respiratory depression when given intravenously. This same study also showed seizures in many of the surviving mice from the mitragynine group. 7-OH-MIT has been described as a "prototypical" compound to develop a new generation of opioids with an improved safety profile. In an electrical stimulation test using guinea-pig ileum, 7-OH-MIT showed opioid agonist potency 13-fold higher than morphine.
Branched-chain amino acid aminotransferase (BCAT), also known as branched-chain amino acid transaminase, is an aminotransferase enzyme (EC 2.6.1.42) which acts upon branched-chain amino acids (BCAAs). It is encoded by the BCAT2 gene in humans. The BCAT enzyme catalyzes the conversion of BCAAs and α-ketoglutarate into branched chain α-keto acids and glutamate. The structure to the right of branched chain amino acid aminotransferase was found using X-ray diffraction with a resolution of 2.20 Å. The branched-chain amino acid aminotransferase found in this image was isolated from mycobacteria. This protein is made up of two identical polypeptide chains, totaling 372 residues. The biological function of branched-chain amino acid aminotransferases is to catalyse the synthesis or degradation of the branched chain amino acids leucine, isoleucine, and valine. In humans, branched chain amino acids are essential and are degraded by BCATs.
== Selected publications == Addona, T. A.; et al. (2009). "Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma". Nature Biotechnology. 27 (7): 633–641. doi:10.1038/nbt.1546. Petrotchenko, E. V.; Borchers, C. H. (2022). "Protein Chemistry Combined with Mass Spectrometry for Protein Structure Determination". Chemical Reviews. 122 (8): 7488–7499. doi:10.1021/acs.chemrev.1c00302. Mohammed, Y.; et al. (2025). "SysQuan: Repurposing SILAC Mice for the Cost-Effective Absolute Quantitation of the Human Proteome". Molecular & Cellular Proteomics. 24 (6): 100974. doi:10.1016/j.mcpro.2025.100974.
Sources: en.wikipedia.org
=== Founding === Wilber Hardee (1918–2008) opened his namesake restaurant in Greenville, North Carolina, on September 3, 1960. After a year of success, Wilber decided to look into expanding his restaurant and opening another location so he met with James Gardner and Leonard Rawls to discuss doing so. Shortly thereafter, the first company store was opened in Rocky Mount, North Carolina, in May 1961 by James Carson Gardner and Leonard Rawls at 329 North Church Street in Rocky Mount, known within the chain as building number 1. That location was demolished in 2007 and replaced with a veterans' park named after Jack Laughery, a former Hardee's chairman and military veteran. According to Wilber Hardee, Gardner and Rawls won a controlling share of the company from him during a game of poker. After realizing that he had lost control over his namesake company, Hardee sold his remaining shares to them as well. However, this story has been disputed by Gardner & Rawls, who bought out Wilber Hardee and began establishing franchises in 1961. According to Jack Laughery, CEO of Hardee's from 1975 to 1990, "Leonard put together an organization with relatively little capital. If it weren't for him and Jim Gardner, there wouldn't be anything of Hardee's Food Systems." Rawls and Gardner sold their first franchises to a small group of longtime friends and acquaintances who formed their own companies and over time, built hundreds more franchised locations. Hardee's Food Systems went public in 1963 with Rawls as president.
=== Synthesis === There are several patented methods for the synthesis of chlorphenamine. In one example, 4-chlorophenylacetonitrile is reacted with 2-chloropyridine in the presence of sodium amide to form 4-chlorophenyl(2-pyridyl)acetonitrile. Alkylating this with 2-dimethylaminoethylchloride in the presence of sodium amide gives γ-(4-chlorphenyl)-γ-cyano-N,N-dimethyl-2-pyridinepropanamine, the hydrolysis and decarboxylation of which lead to chlorphenamine.
== Beta-2 agonists == Beta-2 agonist is a drug that opens the bronchial airways and often helps build muscle. Agonist is often referred to as a drug that stimulates natural processes in the body and beta-2 to a cell receptor. They are clinically used to help asthma patients. Yet, the abuse of beta-3 agonists can be used as an enhancer. Examples of beta-2 agonists are: bambuterol, formoterol, salbutamol, and salmeterol.
Despite the Conscription Law of 1873, and all the reforms and progress, the new Japanese army was still untested. That all changed in 1877, when Saigō Takamori led the last rebellion of the samurai in Kyūshū. In February 1877, Saigō left Kagoshima with a small contingent of soldiers on a journey to Tokyo. Kumamoto castle was the site of the first major engagement when garrisoned forces fired on Saigō's army as they attempted to force their way into the castle. Rather than leave an enemy behind him, Saigō laid siege to the castle. Two days later, Saigō's rebels, while attempting to block a mountain pass, encountered advanced elements of the national army en route to reinforce Kumamoto castle. After a short battle, both sides withdrew to reconstitute their forces. A few weeks later, the national army engaged Saigō's rebels in a frontal assault at what later known as the Battle of Tabaruzaka. During this eight-day-battle, Saigō's nearly ten thousand strong army battled hand-to-hand the equally matched national army. Both sides suffered nearly four thousand casualties during this engagement. Due to conscription, however, the Japanese army was able to reconstitute its forces, while Saigō's was not. Later, forces loyal to the emperor broke through rebel lines and managed to end the siege on Kumamoto Castle after fifty-four days. Saigō's troops fled north and were pursued by the national army. The national army caught up with Saigō at Mt. Enodake. Saigō's army was outnumbered seven-to-one, prompting a mass surrender of many samurai.
Sources: en.wikipedia.org
== Function == As well as C. maenas, CCAP has cardioacceleratory properties in Manduca sexta and Drosophila melanogaster; it is a highly conserved protein found in species as diverse as moths and fruit flies in addition to the crustacean it was originally identified in. Under specific conditions, CCAP has also been shown to induce cardiac reversal in M. sexta and D. melanogaster. Since CCAP was first identified and its possible role suggested, it has been proven it serves many other functions. It regulates release of adipokinetic hormone during sustained flight in L. migratoria. It is also important in metabolism and digestion in other species; CCAP is involved as a hormone in the cockroach Periplaneta americana by upregulating digestive hormones after the insect has fed on nutritional matter. In the crab Cancer borealis CCAP controls passage of food through the foregut by modulating the stomatogastric ganglion's pyloric rhythm. This suggests CCAP is involved primarily in movement of food along the gut, facilitating digestion by secretion of digestive hormones and increasing flow of blood. The effects of CCAP on the reproductive organs of females of the species L. migratoria have also been studied. The peptide stimulates the contraction of the oviducts and spermatheca. There is no CCAP or CCAP-like immunoreactivity shown in the oviduct or the nerves innervating the oviduct so it is probable that CCAP acts as a neurohormone to perform these functions. CCAP is one of several peptides and hormones to be involved in the moulting process of crustaceans and insects.
Clinical trials of isotretinoin, etidronate with oral corticosteroids, and perhexiline maleate have failed to demonstrate effectiveness, though the variable course of the disease and small prevalence induces uncertainty. A handful of pharmaceutical companies focused on rare diseases are currently in varying stages of investigation into different therapeutic approaches for FOP. In August 2015, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted La Jolla Pharmaceuticals orphan drug designation for two novel compounds for FOP. The compounds are small-molecule protein kinase inhibitors designed to selectively block ACVR1 (ALK2). In August 2015, Clementia Pharmaceuticals began the enrollment of children (ages 6 and above) into its Phase II clinical trial investigating palovarotene for the treatment of FOP. Preclinical studies demonstrated that palovarotene, a retinoic acid receptor gamma agonist, blocked abnormal bone formation in animal models by inhibition of secondary messenger systems in the BMP pathway. Clementia licensed palovarotene from Roche Pharmaceuticals, which previously evaluated the compound in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease. Palovarotene received Fast Track designation from the FDA and orphan designations for the treatment of FOP from both the FDA and the European Medicines Agency (EMA). In the pivotal phase 3 MOVE trial published in 2023, Sohonos was shown to reduce new heterotropic ossification by 54-60%.
=== Complications === Compartment syndrome is a clinical diagnosis, i.e., no diagnostic test conclusively proves its presence or absence, but direct measurement of the pressure in a fascial compartment, and the difference between this pressure and the blood pressure, may be used to assess its severity. High pressures in the compartment and a small difference between compartment pressure and blood pressure indicate that the blood supply is likely to be insufficient, and that surgical intervention may be needed. Disseminated intravascular coagulation, another complication of rhabdomyolysis and other forms of critical illness, may be suspected based on unexpected bleeding or abnormalities in hematological tests, such as a decreasing platelet count or prolongation of the prothrombin time. The diagnosis can be confirmed with standard blood tests for DIC, such as D-dimer.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.